Results 261 to 270 of about 25,608 (312)
Some of the next articles are maybe not open access.
2014
Many pain sufferers have difficultly using oral dosages or injections of medications, bringing about the need for an alternative means of delivery for both over the counter and prescription medications. A promising option is medicated patches that can transfer pain relieving drugs through the skin to a localized area.
Gradisher, Logan, Stephens, Analisa
openaire +1 more source
Many pain sufferers have difficultly using oral dosages or injections of medications, bringing about the need for an alternative means of delivery for both over the counter and prescription medications. A promising option is medicated patches that can transfer pain relieving drugs through the skin to a localized area.
Gradisher, Logan, Stephens, Analisa
openaire +1 more source
CNS Drugs, 2008
Rotigotine is a non-ergolinic dopamine receptor agonist, formulated as a silicone-based transdermal patch, which has been evaluated for use in the treatment of adults with moderate to severe restless legs syndrome (RLS). Transdermal rotigotine improved the symptoms of RLS in two well designed 6-month trials in adults with idiopathic, moderate to severe
Claudine M, Baldwin, Gillian M, Keating
openaire +2 more sources
Rotigotine is a non-ergolinic dopamine receptor agonist, formulated as a silicone-based transdermal patch, which has been evaluated for use in the treatment of adults with moderate to severe restless legs syndrome (RLS). Transdermal rotigotine improved the symptoms of RLS in two well designed 6-month trials in adults with idiopathic, moderate to severe
Claudine M, Baldwin, Gillian M, Keating
openaire +2 more sources
Skin tolerability of transdermal patches
Expert Opinion on Drug Delivery, 2011Transdermal patch systems are an effective method of administering active ingredients through the skin, with considerable advantages over other drug delivery routes, for example, maintenance of constant plasma drug levels and avoidance of first-pass metabolism.
Johannes, Wohlrab, B, Kreft, B, Tamke
openaire +2 more sources
Fentanyl transdermal patches induced chemical leucoderma
BMJ Supportive & Palliative Care, 2021Chemical leucoderma is defined as hypopigmentation or vitiligo-like hypomelanosis caused by repeated chemical exposure, and the diagnosis can be made clinically. Chemical leucoderma induced by fentanyl transdermal patches is rare. This case report involves a 53-year-old man with chronic back pain caused by herniated nucleus pulposus at the L4–L5 level.
Sanhapan Wattanapisit +3 more
openaire +2 more sources
Deaths With Transdermal Fentanyl Patches
American Journal of Forensic Medicine & Pathology, 2010Fentanyl is a potent Schedule II narcotic analgesic recommended for use in the management of unremitting pain not controlled by morphine or other opiate/opioid drugs. The danger inherent to fentanyl is its potency (greater than 50-100 times that of morphine) and rapidity of action, causing respiratory depression within minutes of administration ...
openaire +2 more sources
Transdermal Fentanyl Patches in Small Animals
Journal of the American Animal Hospital Association, 2004Fentanyl citrate is a potent opioid that can be delivered by the transdermal route in cats and dogs. Publications regarding transdermal fentanyl patches were obtained and systematically reviewed. Seven studies in cats and seven studies in dogs met the criteria for inclusion in this review.
Erik H, Hofmeister, Christine M, Egger
openaire +2 more sources
Fatal misuse of transdermal fentanyl patches
Forensic Science International, 2019Fentanyl is a potent synthetic opioid with a variety of possible applications. Transdermal fentanyl patches are regularly prescribed for patients with severe chronic or cancer-related pain. The potential for abuse is well-known and cases associated with illicit fentanyl intake are common.
J. Geile +4 more
openaire +2 more sources
Childhood Poisoning Involving Transdermal Nicotine Patches
Pediatrics, 1997Objective. To describe the circumstances, medical complications, and outcomes of children exposed to a transdermal nicotine patch (TNP). Design. Prospective case series; postmarketing surveillance study over a 24-month period. Setting. Thirty-four United States poison centers. Patients.
A, Woolf +3 more
openaire +2 more sources
Transdermal Patch: Recent Advancement
In recent years, a remarkable evolution has been seen in topical drug delivery systems that offer efficient and targeted delivery avenues. This chapter on topical drug delivery systems explores various innovative approaches and their diverse applications in healthcare.Mr. Josef Yakin +3 more
openaire +1 more source
Some issues concerning transdermal nitroglycerin patches
American Heart Journal, 1986There is sufficient evidence to suggest that the duration of action of transdermal nitroglycerin patches is between 20 and 26 hours, as measured by exercise testing. At 24 hours there may be some patient variability, particularly with lower doses; however, the majority of patients show an increase in exercise time at 24 hours.
openaire +2 more sources